Evidence map›Paper›PMID 39457583›Full record

ArticleBiomedicines2024

Genetic and Neurodevelopmental Markers in Schizophrenia-Spectrum Disorders: Analysis of the Combined Role of the

Maria Guardiola-Ripoll, Alejandro Sotero-Moreno, Boris Chaumette, Oussama Kebir, Noemí Hostalet, Carmen Almodóvar-Payá, Mónica Moreira, Maria Giralt-López, Marie-Odile Krebs, Mar Fatjó-Vilas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Guardiola-RipollFIDMAG Germanes Hospitalàries Research Foundation, 08830 Sant Boi de Llobregat, Spain.ORCID 0000-0001-6949-5687
Alejandro Sotero-MorenoFIDMAG Germanes Hospitalàries Research Foundation, 08830 Sant Boi de Llobregat, Spain.
Boris ChaumetteUniversité Paris Cité, Institute of Psychiatry and Neuroscience of Paris (INSERM U1266), GHU-Paris Psychiatrie et Neurosciences, 75014 Paris, France.ORCID 0000-0002-1313-2788
Oussama KebirUniversité Paris Cité, Institute of Psychiatry and Neuroscience of Paris (INSERM U1266), GHU-Paris Psychiatrie et Neurosciences, 75014 Paris, France.
Noemí HostaletFIDMAG Germanes Hospitalàries Research Foundation, 08830 Sant Boi de Llobregat, Spain.ORCID 0000-0002-6522-3999
Carmen Almodóvar-PayáFIDMAG Germanes Hospitalàries Research Foundation, 08830 Sant Boi de Llobregat, Spain.ORCID 0000-0002-1952-1581
Mónica MoreiraServei de Psiquiatria Infantil i de l'Adolescència, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.ORCID 0000-0002-6700-7042
Maria Giralt-LópezServei de Psiquiatria Infantil i de l'Adolescència, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.ORCID 0000-0003-4555-152X
Marie-Odile KrebsUniversité Paris Cité, Institute of Psychiatry and Neuroscience of Paris (INSERM U1266), GHU-Paris Psychiatrie et Neurosciences, 75014 Paris, France.
Mar Fatjó-VilasFIDMAG Germanes Hospitalàries Research Foundation, 08830 Sant Boi de Llobregat, Spain.ORCID 0000-0001-9963-6241

Funding

Instituto de Salud Carlos III PI20/01002
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CNR1dermatoglyphicsendocannabinoid systemneurodevelopmental biomarkersschizophrenia-spectrum disorders

Identifiers

PMID39457583
PMCPMC11505170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.